Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + omega-3 fatty acids
- Development stage
- Unknown
- Lead developer
- Columbia University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of the biguanide metformin and marine-derived omega-3 polyunsaturated fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It is being investigated in a pilot clinical trial (NCT02278965) led by Katherine D. Crew at Columbia University for its feasibility and biomarker modulation in women with a history of early-stage breast cancer. Metformin acts primarily by activating AMP-activated protein kinase (AMPK), which regulates metabolic pathways and inhibits hepatic glucose production. Omega-3 fatty acids modulate inflammatory pathways, act as ligands for GPR120 (FFAR4), and inhibit pro-inflammatory eicosanoid synthesis. The study aims to evaluate changes in breast tissue, blood biomarkers, and mammographic density over a one-year period to assess the potential for breast cancer prevention and survivorship support.
- Other names
- Metformin and Omega-3 Fatty AcidsMetformin and Omega-3EPA/DHA and Metformin
02
Targets
FFAR4 (Free fatty acid receptor 4)AMPK (Adenosine monophosphate–activated protein kinase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on metformin + omega-3 fatty acids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + omega-3 fatty acids.